
The FDA approved giredestrant plus everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer.
Expert oncologist Aditya Bardia, MD, reflects on data from the TROPION-Breast01 trial of dato-DXd versus chemotherapy in metastatic HR+/HER2– breast cancer following ESMO 2023.
Datopotamab deruxtecan (Dato-DXd) vs Chemotherapy in Previously-treated Inoperable or Metastatic Hormone Receptor-positive, HER2-negative (HR+/HER2–) Breast Cancer: Primary Results from the Randomized Phase 3 TROPION-Breast01 Trial
Background
Study Design
Results






